<DOC>
	<DOCNO>NCT00835211</DOCNO>
	<brief_summary>The objective study compare single-dose relative bioavailability TEVA Aventis Pharmaceuticals ( DDAVPÂ® ) 0.2 mg desmopressin acetate tablet follow 0.8 mg dose fasting condition .</brief_summary>
	<brief_title>Desmopressin Acetate 0.2 mg Tablets , Fasting</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Healthy adult nonsmoker ( least 3 month ) light smoke ( le 10 cigarette per day least 3 month ) male female subject , 1855 year age ; Weighing least 60 kg male 52 kg female ; Subjects body mass index ( BMI ) less 30 ; Medically healthy subject clinically normal laboratory profile ECGs ; Females childbearing potential either sexually inactive ( abstinent ) 14 day prior first dose throughout study use one follow acceptable birth control method : surgically sterile ( tubal ligation , hysterectomy , bilateral oophorectomy ) 6 month minimum . Proof required hysterectomy oophorectomy ; IUD place least 3 month ; barrier method ( condom , diaphragm ) spermicide least 14 day prior first dose throughout study ; surgical sterilization partner ( vasectomy 6 month minimum ) ; hormonal contraceptive least 3 month prior first dose study . Other birth control method deem acceptable . Postmenopausal woman amenorrhea least 2 year eligible . Voluntarily consent participate study . Female subject pregnant lactating . Subjects special diet ( whatever reason ) 28 day prior first dose throughout study . Any clinically significant illness within 4 week prior dose . Subjects medical condition require regular treatment prescription drug . The use pharmacological agent know significantly induce inhibit drugmetabolizing enzyme within 30 day prior first dose . Subjects , completion study , would donate excess : 500 mL blood and/or plasma 14 day ; 1500 mL blood and/or plasma 180 day ; 2500 mL blood and/or plasma 1 year . Subjects donate plasma within 30 day prior first dose . Subjects ahd participate another clinical trial within 30 day prior first dose . Subjects tolerate venipuncture . History presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease . In addition , history presence : hypersensitivity idiosyncratic reaction desmopressin synthetic antidiuretic hormone ; type IIB von Willebrand 's disease ; personal family bleed disorder ; alcoholism drug abuse within past year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>